Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | UK practice: pomalidomide in patients resistant to lenalidomide

Guy Pratt • 7 May 2020
Multiple Myeloma Bortezomib Dexamethasone Pomalidomide

Guy Pratt, MD, FRCP, FRCPath, of University of Birmingham, Birmingham, UK, reviews data coming from the OPTIMISMM study (NCT01734928). This sub-analysis looked at patients with multiple myeloma treated with pomalidomide, bortezomib and dexamethasone after one prior line of therapy in patients pre-treated with bortezomib. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Guy Pratt

1:54
Highlights in myeloma from BSH
Guy Pratt • 4 Apr 2022
1:44
Optimal treatment sequencing in multiple myeloma
Guy Pratt • 4 Apr 2022
1:16
Latest advances in immunotherapy for multiple myeloma: targets, alloCAR-Ts & immunomodulatory drugs
Guy Pratt • 4 Apr 2022
2:17
Cilta-cel: a paradigm shift in the treatment of multiple myeloma
Guy Pratt • 4 Apr 2022

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals